China May Set Reference Prices, Adjust Price Caps For High-Cost Drugs
This article was originally published in PharmAsia News
China’s National Development and Reform Commission has publicly stated that drug price control method will change from retail price caps to reference prices and that some high-priced medicines will undergo retail price limit adjustment.
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.